For research use only. Not for therapeutic Use.
Dalcetrapib（Cat No.:I002624）, also known as JTT-705 or RO-4607381, is a potent inhibitor of recombinant human cholesteryl ester transfer protein (HTTP). It exhibits an IC50 value of 0.2 μM, indicating its ability to effectively inhibit the activity of CETP. Dalcetrapib is specifically designed to increase the levels of high-density lipoprotein (HDL) cholesterol in the bloodstream. By inhibiting CETP, it prevents the transfer of cholesterol from HDL to other lipoproteins, ultimately leading to increased plasma HDL cholesterol levels. Dalcetrapib holds promise as a potential therapeutic agent for raising HDL cholesterol and potentially reducing the risk of cardiovascular diseases.
| Catalog Number | I002624 |
| CAS Number | 211513-37-0 |
| Synonyms | S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate |
| Molecular Formula | C₂₃H₃₅NO₂S |
| Purity | ≥95% |
| Target | CETP |
| Solubility | DMSO > 50 mg/mL Ethanol > 50 mg/mL |
| Storage | -20°C |
| IC50 | 0.2 uM [1] |
| IUPAC Name | S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate |
| InChI | InChI=1S/C23H35NO2S/c1-5-18(6-2)16-23(14-10-7-11-15-23)22(26)24-19-12-8-9-13-20(19)27-21(25)17(3)4/h8-9,12-13,17-18H,5-7,10-11,14-16H2,1-4H3,(H,24,26) |
| InChIKey | YZQLWPMZQVHJED-UHFFFAOYSA-N |
| SMILES | CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C |
| Reference | </br>1:Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys. Brodeur MR, Rhainds D, Charpentier D, Mihalache-Avram T, Mecteau M, Brand G, Chaput E, Perez A, Niesor EJ, Rhéaume E, Maugeais C, Tardif JC.J Lipid Res. 2017 May 17. pii: jlr.M068940. doi: 10.1194/jlr.M068940. [Epub ahead of print] PMID: 28515138 Free Article</br>2:CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib. Tardif JC, Rhainds D, Rhéaume E, Dubé MP.Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):396-400. doi: 10.1161/ATVBAHA.116.307122. Epub 2017 Jan 26. PMID: 28126828 </br>3:Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Nicholls SJ, Niesor EJ, Olsson AG, Shah PK, Tardif JC, Kittelson J, Schwartz GG.J Am Coll Cardiol. 2016 Dec 6;68(22):2488-2490. doi: 10.1016/j.jacc.2016.09.932. No abstract available. PMID: 27908356 </br>4:Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y, Fouodjio R, Provost S, Boulé M, Alem S, Grégoire JC, L/’Allier PL, Ibrahim R, Guertin MC, Mongrain I, Olsson AG, Schwartz GG, Rhéaume E, Dubé MP.Circ Cardiovasc Genet. 2016 Aug;9(4):340-8. doi: 10.1161/CIRCGENETICS.116.001405. Epub 2016 Jul 14. PMID: 27418594 Free PMC Article</br>5:Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib. Johns DG, Chen Y, Wang SP, Castro-Perez J, Previs SF, Roddy TP.Eur J Pharmacol. 2015 Sep 5;762:256-62. doi: 10.1016/j.ejphar.2015.05.061. Epub 2015 Jun 3. PMID: 26049012 </br>6:Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Tardif JC, Rhéaume E, Lemieux Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L/’Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dubé MP.Circ Cardiovasc Genet. 2015 Apr;8(2):372-82. doi: 10.1161/CIRCGENETICS.114.000663. Epub 2015 Jan 11. PMID: 25583994 Free Article</br>7:Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations. Niesor EJ, Kallend D, Bentley D, Kastelein JJ, Kees Hovingh G, Stroes ES.Lipids. 2014 Dec;49(12):1245-9. doi: 10.1007/s11745-014-3956-x. Epub 2014 Oct 4. PMID: 25281277 </br>8:Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters. Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.Eur J Pharmacol. 2014 Oct 5;740:135-43. doi: 10.1016/j.ejphar.2014.06.022. Epub 2014 Jul 5. PMID: 25008069 </br>9:Pharmacokinetics and disposition of dalcetrapib in rats and monkeys. Takubo H, Ishikawa T, Kuhlmann O, Nemoto H, Noguchi T, Nanayama T, Komura H, Kogayu M.Xenobiotica. 2014 Dec;44(12):1117-26. doi: 10.3109/00498254.2014.932471. Epub 2014 Jun 23. PMID: 24954481 </br>10:Dalcetrapib in patients with an acute coronary syndrome. Tomoda H.N Engl J Med. 2013 Feb 28;368(9):869. doi: 10.1056/NEJMc1300057#SA1. No abstract available. PMID: 23445099 |
